Press releases

14
Sep 2026
08:40 E.S.T.

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

Read more
11
Sep 2026
17:30 E.S.T.

Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update

Read more
1
Sep 2026
11:09 E.S.T.

Cellectis Announces Participation in Upcoming Investor Conferences

Read more
6
Aug 2026
16:32 E.S.T.

Cellectis Reports Financial Results for the Second Quarter 2026

Read more
30
Jul 2026
20:30 E.S.T.

Cellectis to Report Second Quarter Financial Results on August 6, 2026

Read more
25
Jun 2026
20:30 E.S.T.

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

Read more
11
Jun 2026
06:40 E.S.T.

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

Read more
9
Jun 2026
20:30 E.S.T.

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Read more
20
May 2026
20:30 E.S.T.

Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

Read more
12
May 2026
13:30 E.S.T.

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US